Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis is a clinical-stage biopharmaceutical company with a differentiated pipeline centered on TYK2 inhibition, including envudeucitinib for PsO and SLE and A-005 for CNS diseases, which gives it exposure to large, underserved autoimmune and neuroinflammatory markets if development succeeds. The bullish view rests on the commercial potential embedded in A-005, with an estimated $1.31 NPV/share, 2029E launch assumptions in multiple sclerosis, a 0.85% market share ramp, $100k initial pricing, and $139.4 mm peak 2035E sales at a 15% launch probability, while envu also offers upside if it can compete effectively in psoriasis and SLE. Although the company faces meaningful financing, regulatory, and competitive risks, the need for additional capital is tied to R&D and launch execution rather than a lack of scientific opportunity, and the presence of multiple approved and developing comparators underscores the scale of the addressable markets that could reward successful clinical and commercial execution.

Alumis is negatively exposed to fundamental execution risk because its lead assets have already shown mixed and in some cases disappointing data, including the LUMUS study missing key endpoints and the Phase I failure of A-005, which weakens confidence in both the TYK2 platform and the broader CNS strategy. Even where envudeucitinib has delivered strong phase III psoriasis efficacy in 2026, the opportunity remains constrained by intense competition from approved and late-stage oral therapies, potential partner dependence for commercialization, and the possibility that regulatory or commercial outcomes prove narrower than expected, while the company still faces ongoing R&D burn and dilution risk before profitability. Financially, the case is further pressured by the need for additional capital, a 25% launch probability and only $81.3 mm peak 2035E sales in SLE, a 15% launch probability and $139.4 mm peak 2035E sales for A-005 in MS, and a view that even envu’s larger psoriasis opportunity requires $100k pricing and a 90% launch probability to support an estimated $3.4 bn peak 2035E sales.